retinitis pigmentosa

Kiora Pharmaceuticals Advances Key Clinical Programs

ENCINITAS, Calif., August 7, 2026 Kiora Pharmaceuticals reported second quarter 2026 financial results while highlighting continued progress across its...

By cGxPwire Editor
August 8, 2026

Bio-Pharma

Ocugen Signs OCU400 Licensing Agreement with Roots Pharma

MALVERN, Pa., July 13, 2026 Ocugen announced the signing of a binding term sheet with Roots Pharmaceutical and its...

By cGxPwire Editor
July 14, 2026

.Clinical

Nanoscope Therapeutics Highlights MCO-010 Vision Data at ASGCT 2026

DALLAS, May 11, 2026 Nanoscope Therapeutics announced multiple scientific presentations at the American Society of Gene and Cell Therapy...

By cGxPwire Editor
May 12, 2026

Bio-Pharma

Opus Initiates Gene Therapy Trial for MERTK Retinal Disease

Research Triangle Park, N.C. | January 27, 2026 — Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on inherited...

By cGxPwire Editor
January 28, 2026

Bio-Pharma

Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation

Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...